These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26239977)

  • 1. Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.
    Lehoux D; Ostiguy V; Cadieux C; Malouin M; Belanger O; Far AR; Parr TR
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6501-5. PubMed ID: 26239977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects.
    Bhavnani SM; Owen JS; Loutit JS; Porter SB; Ambrose PG
    Diagn Microbiol Infect Dis; 2004 Oct; 50(2):95-102. PubMed ID: 15474317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.
    Rubino CM; Bhavnani SM; Moeck G; Bellibas SE; Ambrose PG
    Antimicrob Agents Chemother; 2015; 59(6):3365-72. PubMed ID: 25824211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.
    Fetterly GJ; Ong CM; Bhavnani SM; Loutit JS; Porter SB; Morello LG; Ambrose PG; Nicolau DP
    Antimicrob Agents Chemother; 2005 Jan; 49(1):148-52. PubMed ID: 15616289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftriaxone bone penetration in patients with septic non-union of the tibia.
    Garazzino S; Aprato A; Baietto L; D'Avolio A; Maiello A; De Rosa FG; Aloj D; Siccardi M; Biasibetti A; Massè A; Di Perri G
    Int J Infect Dis; 2011 Jun; 15(6):e415-21. PubMed ID: 21497532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics and tissue penetration of teicoplanin.
    Novelli A; Mazzei T; Reali EF; Mini E; Periti P
    Int J Clin Pharmacol Res; 1989; 9(3):233-7. PubMed ID: 2526102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
    Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
    Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers.
    Kumar A; Mann HJ; Keshtgarpour M; Flynn MA; Deng H; Far AR; Parr TR; Moriarty SR
    Int J Artif Organs; 2011 Nov; 34(11):1067-74. PubMed ID: 22183520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study.
    Darpo B; Lee SK; Moon TE; Sills N; Mason JW
    J Clin Pharmacol; 2010 Aug; 50(8):895-903. PubMed ID: 20484618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of enrofloxacin following intravenous and intramuscular administration in Angora rabbits.
    Elmas M; Uney K; Yazar E; Karabacak A; Traş B
    Res Vet Sci; 2007 Apr; 82(2):242-5. PubMed ID: 16930647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oritavancin: A Long-Half-Life Lipoglycopeptide.
    Saravolatz LD; Stein GE
    Clin Infect Dis; 2015 Aug; 61(4):627-32. PubMed ID: 25900171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and excretion of dalbavancin in the rat.
    Cavaleri M; Riva S; Valagussa A; Guanci M; Colombo L; Dowell J; Stogniew M
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii31-5. PubMed ID: 15750035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and bone tissue concentrations of lincomycin following intravenous and intramuscular administrations to cats.
    Albarellos GA; Montoya L; Denamiel GA; Velo MC; Landoni MF
    J Vet Pharmacol Ther; 2012 Dec; 35(6):534-40. PubMed ID: 22132730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
    Bouza E; Burillo A
    Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the pharmacokinetics of imipenem after intravenous and intrathecal administration in rabbits.
    Wang Y; Qiu L; Dong J; Wang B; Shi Z; Liu B; Wang W; Zhang J; Cai S; Ye G; Cai X
    Eur Rev Med Pharmacol Sci; 2013 Mar; 17(6):711-9. PubMed ID: 23609353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of florfenicol after intravenous and intramuscular administration in New Zealand White rabbits.
    Koc F; Ozturk M; Kadioglu Y; Dogan E; Yanmaz LE; Okumus Z
    Res Vet Sci; 2009 Aug; 87(1):102-5. PubMed ID: 19062054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teicoplanin: Part 2. Evaluation of its use in the biliary system.
    Antrum RM; Bibby SR; Ramsden CH; Kester RC
    Drugs Exp Clin Res; 1989; 15(1):25-7. PubMed ID: 2526009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teicoplanin: Part 1. An evaluation of the concentrations seen in serum and the subcutaneous fat of the relatively ischaemic lower limb following a single intravenous bolus.
    Antrum RM; Bibby SR; Ramsden CH; Kester RC
    Drugs Exp Clin Res; 1989; 15(1):21-3. PubMed ID: 2526008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capillary electrophoretic determination of thiamphenicol in turkeys serum and its pharmacokinetic application.
    Kowalski P
    J Pharm Biomed Anal; 2007 Jan; 43(1):222-7. PubMed ID: 16857337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.